Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the ...

Wall Street analysts forecast that Pfizer (PFE) will report quarterly earnings of $0.66 per share in its upcoming release, pointing to a year-over-year decline of 37.7%. It is anticipated that ...

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the ...

In September, the telecommunications giant announced it was boosting its dividend by 1.25 cents a share to $0.69 per share, ...

Pfizer (PFE) posted notable earnings growth, with net profit margins improving to 15.6%, a lift from the previous period’s 7% ...

Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. As a result, Vertex should be worth ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

In the latest close session, Pfizer (PFE) was down 1.09% at $24.50. This move lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow experienced a rise of 0.34%, and the technology-dominated ...